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Abstract
Cerebrovascular pathologies occur in up to 80% of cases of
Alzheimer’s disease; however, the underlying mechanisms that
lead to perivascular pathology and accompanying blood–brain
barrier (BBB) disruption are still not fully understood. We have
identified previously unreported mutations in colony stimulating
factor-1 receptor (CSF-1R) in an ultra-rare autosomal dominant
condition termed adult-onset leucoencephalopathy with axonal
spheroids and pigmented glia (ALSP). Cerebrovascular pathologies
such as cerebral amyloid angiopathy (CAA) and perivascular p-Tau
were some of the primary neuropathological features of this
condition. We have identified two families with different domi-
nant acting alleles with variants located in the kinase region of
the CSF-1R gene, which confer a lack of kinase activity and signal-
ling. The protein product of this gene acts as the receptor for 2
cognate ligands, namely colony stimulating factor-1 (CSF-1) and
interleukin-34 (IL-34). Here, we show that depletion in CSF-1R
signalling induces BBB disruption and decreases the phagocytic
capacity of peripheral macrophages but not microglia. CSF-1R
signalling appears to be critical for macrophage and microglial
activation, and macrophage localisation to amyloid appears
reduced following the induction of Csf-1r heterozygosity in
macrophages. Finally, we show that endothelial/microglial cross-
talk and concomitant attenuation of CSF-1R signalling causes re-
modelling of BBB-associated tight junctions and suggest that
regulating BBB integrity and systemic macrophage recruitment to
the brain may be therapeutically relevant in ALSP and other
Alzheimer’s-like dementias.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterised by a gradual decline in cognitive function
and is the most common cause of dementia in the elderly.
Currently, there are approximately 36 million people worldwide
who suffer from AD and other dementias and there are no
approved medicines to prevent disease progression. The central
neuropathological hallmarks of AD are as follows: (i) the extracel-
lular accumulation of amyloid-β (Aβ) in parenchymal plaques and
(ii) the formation of intracellular neurofibrillary tangles (NFTs)
composed of hyperphosphorylated forms of the microtubule-asso-
ciated protein tau. Additionally, up to 80% of AD patients display
cerebrovascular pathologies such as cerebral amyloid angiopathy
(CAA) as well as in over 30% of cases of non-Alzheimer’s
dementia (Matthews et al, 2009). CAA is characterised by an
accumulation of Aβ in the parenchymal space, within vessel walls
of arteries (namely the cerebral, leptomeningeal and parenchymal
arteries) or around small- to medium-sized blood vessels. The
underlying mechanism that leads to Aβ accumulation in this
perivascular pattern is still not fully understood. It is accepted,
however, that CAA can contribute to dementia onset and cogni-
tive decline through increasing susceptibility for microbleeds,
cerebral ischaemia and chronic activation of pro-inflammatory
mechanisms in the surrounding parenchyma (Kinnecom et al,
2007; Vukic et al, 2009).
Recently, we have examined post-mortem brain tissues from
two families with an ultra-rare condition termed adult-onset
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leucoencephalopathy with axonal spheroids and pigmented glia
(ALSP). Individuals in this family presented clinically with early-
onset dementia (in their forties) that had been reported within the
family previously. Indeed, many of the reported symptoms for ALSP
are akin to those reported in AD, namely depression, cognitive
impairment, gait disturbances, speech problems and overt neurode-
generation. Adult-onset leucoencephalopathies accompanied by
spheroids and pigmented glia were initially categorised as two main
conditions, hereditary diffuse leucoencephalopathy with axonal
spheroids (HDLS) and familial pigmentary orthochromatic leucodys-
trophy (POLD). While these clinical conditions have been known
for nearly 40 years as distinct entities(Van Bogaert, 1936; Axelsson
et al, 1984), the genetic cause of the two were reported within the
past 10 years as being associated with dominant acting mutations in
the colony stimulating factor-1 receptor (CSF-1R) gene (Rademakers
et al, 2011). Due to the shared genetic aetiology of the conditions
(Nicholson et al, 2013), they are now considered to be part of the
spectrum of the same disease, which has been termed ALSP (Adams
et al, 2018).
CSF-1R is activated via common structural principles by two
distinct cytokine ligands, namely colony stimulating factor-1 (CSF-
1) and interleukin-34 (IL-34) (Elegheert et al, 2011; Ma et al, 2012;
Felix et al, 2013, 2015) which are both essential for microglial
viability, development and proliferation (Askew et al, 2017; Bohlen
et al, 2017; Wu et al, 2018). CSF-1R is also critical for myeloid
lineage cell differentiation, as well as that of peripheral monocytes
into circulating and tissue-resident macrophages (Wang et al, 2012;
Rojo et al, 2019), and was recently found to be mutated in gain-of-
function pathologic variants in histiocytic neoplasms (Durham et al,
2019). While CSF-1R is expressed in some cells of the adult brain
under homeostasis, namely microglia, it and its ligands have been
shown to be upregulated and neuroprotective in mouse disease
models of AD and epilepsy (Luo et al, 2013; Schwarzer et al, 2019).
In addition to CSF-1R signalling appearing to be a critical pathway
for responding to CNS insult, IL-34 is secreted by neuronal cells
under normal conditions and can enhance neuroprotective effects of
microglia in response to stimuli such as oligomeric amyloid (Sch-
warzer et al, 2019). While CSF-1R has been detected previously in
mouse endothelial cells within the brain and spinal cord (Jin et al,
2014), and exhibits endothelial expression in human cortical tissue
(Uhlen et al, 2015), it has still not been fully confirmed that brain
endothelial cells actually express the protein. In this regard, the
expression pattern of CSF1R in the brain endothelium has yet to be
fully characterised.
As CSF-1R is essential for the survival of the vast majority of
microglial populations, it has recently become a commonly targeted
receptor in drug development programmes for epilepsy and AD.
CSF-1R inhibition in pre-clinical models using small molecules such
as PLX3397 and PLX5622 has been shown to be effective in deplet-
ing up to 99% of microglia within 3 weeks of administration in
chow (Luo et al, 2013; Rice et al, 2015; Dagher et al, 2015; Renee
et al, 2015; Spangenberg et al, 2016, 2019; Bohlen et al, 2017; Singh
et al, 2017; Elmore et al, 2018; Srivastava et al, 2018). Many of these
studies report beneficial outcomes in mouse models of AD including
reduced plaque burden (Rice et al, 2015), neuroinflammation (Span-
genberg et al, 2016) and improved cognition (Dagher et al, 2015).
However, these microglia-ablation studies have also produced con-
flicting data related to whether microglial ablation affects the rate of
Aβ deposition and cognition improvement. Furthermore, cognitive
improvement has not been sustained following repopulation of the
brain by microglia in these models. Whether the beneficial effects of
CSF-1R inhibition are due to ameliorating a key process in the devel-
opment of AD in these mice, or transiently inhibiting the overall
effects of microglial inflammatory processes on cognition, has not
been established.
Here, we have observed Aβ-associated cerebrovascular pathol-
ogy accompanied by BBB breakdown in 2 separate families with
previously unreported and different dominant acting mutations in
the kinase region of CSF-1R. These mutations lead to a profound
loss of function of CSF-1R and attenuated signalling, rendering
affected individuals essentially haploinsufficient for CSF-1R.
Surprisingly however, we found that microglial cells heterozygous
for Csf-1r retain robust phagocytic ability, but macrophages with
depleted CSF-1R signalling are significantly compromised. We show
that dysregulated CSF-1R-dependent endothelial/microglial cell
crosstalk induces re-modelling of the BBB in mouse and human
and suggests that regulating BBB integrity while promoting macro-
phage recruitment to the brain may be therapeutically viable in
ALSP and other AD-like dementia. Added to this, autologous bone
marrow transplants could show real and meaningful clinical read-
outs in ALSP patients.
Results
Dominant mutations in CSF-1R induce cerebral amyloid
angiopathy (CAA) and cerebrovascular pathology
We identified 2 separate families showing clinical evidence of the
ultra-rare condition ALSP. Concomitantly, we confirmed the pres-
ence of mutations within the kinase region of the CSF-1R gene,
ΔA781_N783 in one family (Fig 1A) and a P824R mutation in
another (Fig 1B). Post-mortem analysis of the brains of 3 geneti-
cally diagnosed ALSP cases revealed extensive cerebral atrophy
(Figs 1C and D and EV1). Widespread white matter Wallerian
degeneration was also observed (Fig 1E). Very extensive axonal
spheroids were apparent when sections of brain tissue were
stained for neurofilament (Fig 1F). Furthermore, widespread cere-
bral amyloid angiopathy (CAA), involving meningeal and intra-
parenchymal blood vessels, was also evident in tandem with
severe arteriosclerosis in subcortical white matter (Fig 1G and H).
An identical pathology was observed in all 3 post-mortem cases of
ALSP. Perivascular accumulation of phosphorylated Tau (P-tau)
(Fig 1I and J) and amyloid-beta (Aβ) was clearly evident, and
observation of such unique pathologies in a single disease points
towards a deficit in the underlying processes through which these
proteins aggregate and/or are cleared across the endothelium that
constitutes the BBB.
Mutations in CSF-1R attenuate kinase activity and signalling
ALSP is primarily inherited in an autosomal dominant manner, and
in these particular families, it results from either a 9-base-pair in-
frame deletion in the CSF-1R gene, (c.2342_2350del) leading to an
Ala781-Arg782-Asn783 deletion, or a single point mutation
(c.2741C > G) leading to a Pro824Arg substitution. These are
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previously unreported mutations in CSF-1R and based on sequence
considerations both mutations would be expected to be found in the
intracellular kinase domain of CSF-1R. Analysis of the structural
context of these mutations using the crystal structure of the kinase
domain of human CSF-1R (pdb entry 2OGV) (Walter et al, 2007)
reveals that the mutated sites localise within highly conserved
sequence cassettes in the C-lobe of the kinase region of CSF-1R
(Fig 2A). In the case of the Ala781-Asn783 deletion mutation, the 3
amino acids are critical for comprising a unique left-handed helical
secondary structural element within the active site of CSF-1R (Fig 2
A). This allows projection of Arg782 to interact with the catalytic
residue Asp778 and the activation loop of CSF-1R. Furthermore,
Ala781 makes key interactions with a hydrophobic core of the C-
lobe (Fig 2A). Therefore, the Ala781-Asn783 deletion mutation
would be predicted to be a loss-of-function mutation and to exhibit
compromised protein stability. Similarly, Pro824 is found at the end
of the activation loop of CSF-1R and nestles into a strictly hydropho-
bic pocket to provide structural anchoring and stability. Thus, a
Pro824Arg mutation would be expected to be overwhelmingly
incompatible with such an environment leading to destabilisation of
both the activation loop of CSF-1R and part of the hydrophobic core
of the C-lobe of the CSF-1R kinase domain (Fig 2A).
A
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Figure 1. Identification of familial variants in CSF-1R.
A, B Family pedigrees for CSF-1R variants ΔA781_N783 and P824R, with Sanger sequencing confirmations for each variant below.
C Cystic encephalomalacia evident in the right inferior frontal lobe secondary to a historical intraparenchymal haemorrhage.
D Extensive atrophy evident in frontal lobe.
E Secondary de-myelination observed with Luxol-Fast Blue stain.
F Wallerian degeneration observed with spheroids apparent following phosphorylated neurofilament staining.
G, H Profound cerebral amyloid angiopathy (CAA), involving meningeal and intraparenchymal blood vessels.
I, J Extensive phospho-tau staining displaying a perivascular pattern of deposition.
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Generation of a native CSF-1R gene in tandem with genes contain-
ing the 2 mutations clearly showed that protein expression levels of
CSF-1R were decreased in both mutations, with no accompanying
decrease in transcriptional activity (Fig 2B and C). Localisation of
CSF-1R is still conserved to the plasma membrane even in the pres-
ence of a CSF-1R mutation, suggestive of no dominant-negative
effect of the mutation (Fig EV2). The concept of mutant CSF-1R
aggregating and accumulating in cells was then explored using a cell
stress array approach. In cells over-expressing CSF-1R with the
P824R variant, out of 84 cell stress-related genes examined only
DDIT3 and CXCL8 had significantly altered gene expression values
when compared to cells expressing native CSF-1R (Appendix Fig S1).
Importantly however, while stimulation of cells expressing native
CSF-1R with recombinant CSF-1 (Fig 2D and E) or IL-34 (Fig 2F and
G) at increasing doses caused increased and dose-dependent ERK
phosphorylation, no ERK phosphorylation was evident in cells
expressing mutant CSF-1R. p-ERK was observed in cells co-express-
ing native and mutant CSF-1R, suggestive of retained function of
native CSF-1R in the presence of variant CSF-1R. The IL-34-medi-
ated increase in p-ERK was reduced in the heterozygous context;
however, in response to CSF-1, similar levels of ERK phosphoryla-
tion were observed in native-only and native-variant transfected
cells. In order to rule out the possibility that absence of CSF-1R
signalling is due to the reduced level of variant CSF-1R, we pre-
treated cells with MG132 which can upregulate variant CSF-1R. No
signalling was observed post-stimulation, confirming loss of func-
tion of CSF-1R signalling in both mutations (Fig EV3).
In order to ascertain a putative mechanism underlying the
control of CSF-1R production and turnover, we examined the
expression of native or mutant CSF-1R in the presence of increasing
doses of an autophagy inducer (rapamycin) (Fig 2H), an autophagy
inhibitor (3-methyladenosine) (Fig 2I) or a proteasomal inhibitor
(MG132) (Fig 2J). Intriguingly, during autophagy inhibition, CSF-1R
protein levels are increased independent of genotype. While autop-
hagy induction also showed a dose-dependent increase in CSF-1R
levels, inhibition of the proteasome appeared to specifically regulate
levels of mutated CSF-1R and not native protein (Fig 2J).
Mutant and non-functioning CSF-1R protein decreases the
phagocytic capacity of peripheral macrophages but not microglia
While CSF-1R is expressed in endothelial cells, the predominant cell
types expressing this protein are immune cells of the myeloid
lineage and microglia. Post-mortem analysis of ALSP patient brains
showed a perivascular accumulation of CD68- and CD163-positive
cells suggestive of peripheral macrophage involvement. To this end
and in order to ascertain the effect of mutated CSF-1R on immune
cell differentiation, we isolated PBMCs from an individual diagnosed
with the ΔA781_N783 CSF-1R mutation and compared them to a
normal healthy donor. Interestingly, there was a very clear deple-
tion of T cells, CD14+ macrophages in addition to B cells. Added to
this, PBMCs from the ALSP patient also showed up to 90% lineage-
negative cells (CD3/14/16/19/20/56) compared to a non-diseased
sample (Fig 3A and B). It was also very clear that macrophages
isolated from patients expressing either CSF-1R mutation displayed
highly dysmorphic cells (Fig 3C). These cells accounted for 30% of
all differentiated macrophages and had a significantly decreased
phagocytic ability compared to macrophages isolated from healthy
donors (Fig 3D–F). As CSF-1R is predominantly expressed in microglial
cells in the adult mouse and human brain, we sought to determine
whether the phagocytic ability of microglial cells was compromised in
mice expressing only a single Csf-1r allele in microglia.
Unexpectedly, there was no difference between the phagocytic
capacity of microglia with reduced CSF-1R signalling. Similarly,
microglia which underwent pharmacological Csf-1r downregulation
using siRNA had no change in the rate of phagocytosis (Fig 3G and
H), and this was further confirmed through genetic Csf-1r reduction
in mice. Primary microglia isolated from WT or microglial/ma-
crophage-specific Csf-1r+/− mice displayed no altered phagocytic
capacity (Fig 3J–I), together suggesting that Csf-1r heterozygosity
was dispensable for microglial phagocytosis. However, when we
examined bone-marrow-derived macrophages (BMDM’s) from the
same animals, the phagocytic ability of Csf-1r+/− BMDMs was signif-
icantly compromised similar to the human PBMCs, indicating a
deficit in peripheral macrophage phagocytosis as opposed to
◀ Figure 2. The ΔA781_N783 and P824R variants in CSF-1R are loss of function and have conserved cellular processing.A Structure-sequence analysis and context of the CSF-1R ΔA781_N783 and P824R variants. Sequences used in the alignment correspond to Uniprot sequences for
CSF-1R as follows: Human P07333, Cynomolgus Monkey A0A2K5WG91, Mouse P09581, Bovine A7Z067, Cat P13369, Zebrafish Q9I8N6.
B Western blot for CSF-1R and Actin in HEK293 cells transfected with native and variant CSF-1R as indicated.
C Densitometry (top) and qPCR analysis of native and variant CSF-1R expression in HEK293 cells relative to native-transfected at 24 and 48 h (****P < 0.0001,
***P < 0.0005, , **P < 0.005 one-way ANOVA with Sidak’s post-test for multiple comparison, n = 3 biological replicates, error bars indicate SEM).
D–G Western blot for phosphorylated and total ERK in HEK293 cells transfected with native and ΔA781_N783 (left) or P824R (right) CSF-1R and treated with CSF-1 (D,
E) or IL-34 (F, G) for 10 min. Horizontal line indicates untreated cells, with increasing concentrations 10, 50 and 100 ng/ml. Corresponding densitometry displays
the ratio of phospho-ERK to total ERK, normalised to the ratio of the untreated control for the native receptor (****P < 0.0001, ***P < 0.0005, **P < 0.01,
*P < 0.05, one-way ANOVA with Sidak’s post-test for multiple comparison, n = 3 biological replicates, , error bars indicate SEM).
H Western blot for CSF-1R in HEK293 cells transfected with native and ΔA781_N783 (top) or P824R (bottom) CSF-1R and treated with rapamycin. Horizontal line
indicates untreated cells, with concentrations 0.1, 0.5, 1, 5, 10 μM. Corresponding densitometry (below) displays the fold change of CSF-1R relative to the untreated
control for each transfection (****P < 0.0001, one-way ANOVA with Sidak’s post-test for multiple comparison to untreated, n = 3 biological replicates, error bars
indicate SEM).
I Western blot for CSF-1R in HEK293 cells transfected with native and ΔA781_N783 (top) or P824R (bottom) CSF-1R and treated with 3-methyladenosine. Horizontal
line indicates untreated cells, with increasing concentrations 0.1, 0.2, 0.5, 1 mM. Corresponding densitometry (below) displays the fold change of CSF-1R relative to
the untreated control for each transfection (****P < 0.0001, *P = 0.0114, one-way ANOVA with Sidak’s post-test for multiple comparison to untreated, n = 3
biological replicates, error bars indicate SEM).
J Western blot for CSF-1R and Actin in HEK293 cells transfected with native and ΔA781_N783 (top) or P824R (bottom) CSF-1R and treated with MG132 or PLX3397.
Horizontal line indicates untreated cells, 20 μM PLX3397, with increasing concentrations 0.1, 0.5, 0.1, 5 μM. Corresponding densitometry (below) displays the fold
change of CSF-1R relative to the untreated control for each transfection (***P = 0.0002, **P = 0.002, one-way ANOVA with Sidak’s post-test for multiple
comparison to untreated, n = 3 biological replicates, error bars indicate SEM).
ª 2020 The Authors EMBO Molecular Medicine 13: e12889 | 2021 5 of 17
Conor Delaney et al EMBO Molecular Medicine
microglial cells (Fig 3L and M). These data suggest that in the
human condition with Csf-1r haploinsufficiency, activated microglia
are still robustly phagocytically active, while it is peripheral macro-
phages that are compromised.
CSF-1R loss affects macrophage/microglial activation and
brain recruitment
In order to ascertain whether endothelial or macrophage CSF-1R is
central to immune cell response to a stimulus such as amyloid
aggregation and clearance across the BBB, we injected amyloid-beta
1-42 unilaterally into the hippocampus of mice lacking a single Csf-
1r allele in microglial/macrophage cells (Fig 4A) or endothelial cells
(Fig 4C). Reduced immune cell infiltration and activation (F4/80
positivity) was only evident in the context of macrophage (Fig 4B)
Csf-1r loss as opposed to endothelial cells (Fig 4D). This is of
particular note in the context of CAA as the patrolling subset of
monocytes in mice known to associate with the cerebral
vasculature (Ly6Clo, Cx3CR1high, CCR2−) develop in a CSF-1R-
dependent manner (Yona et al, 2013). Targeted depletion of these
vessel-associating macrophages has previously been shown to
induce an increase in Aβ load in the brain parenchyma as well as
around the CNS vasculature (Michaud et al, 2013). Additionally,
stimulation of these cells was also able to specifically reduce CAA
load, highlighting the critical role of peripheral CSF-1R-dependent
macrophage activity in driving amyloid clearance at the BBB
(Hawkes & McLaurin, 2009).
Endothelial/microglial crosstalk induces tight junction
re-modelling and BBB disruption in ALSP
As mutations in CSF-1R and a lack of CSF-1R signalling can clearly
induce cerebrovascular pathology in humans, we sought to eluci-
date the cell type responsible for mediating this phenotype. In that
regard, we treated mouse microglial cells with two concentrations
of the CSF-1R inhibitor PLX3397 (Hi, Lo) to observe the indirect
effects of CSF-1R-inhibited microglia conditioned media (Hi-BVCM,
Lo-BVCM) on endothelial cells (Fig 5A). Strikingly, we observed
that cell culture media conditioned by microglia in the absence of
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treatment (Fig 5B). To control for the effects of PLX3397 itself on
endothelial cells, it was also added to endothelial cells. Although
ZO1 and occludin displayed reduced protein levels at 24 h in
response to CSF-1R inhibition alone, the critical BBB-associated tight
junction protein claudin-5 displayed a microglia-specific response to
treatment, with Lo-BVCM reducing protein levels at 24 h (Fig 5C
and D). Hi-BVCM induced a downregulation of Tjp1 expression, as
did PLX3397 itself (Fig 5D). Contrastingly, Ocln appeared to have
been upregulated by untreated microglia conditioned media, an
effect which was reduced in response to Lo-BVCM, and ablated
completely in the case of Hi-BVCM.
To investigate the interactions in the context of both microglia
and endothelial cells having Csf-1r heterozygosity, we isolated
microglial cells from normal mice (WT) or those lacking a single
Csf-1r allele in their microglial cells. We collected conditioned
medium from these cells in addition to collecting conditioned
medium from WT microglial cells where CSF-1R was inhibited using
PLX3397. Subsequently, this microglial conditioned medium (MCM)
was added to confluent monolayers of primary brain microvascular
endothelial cells isolated from WT mice, or mice lacking a single
Csf-1r allele in their endothelial cells (Fig 5E). Intriguingly, MCM
isolated from microglial cells lacking one Csf-1r allele could induce a
potent downregulation of claudin-5 protein levels (Fig 5F and G).
Endothelial cells lacking a single Csf-1r allele did not manifest a
decreased level of claudin-5 in response to MCM treatment;
however, levels of other tight junction components such as occludin
and ZO-1 were decreased in a CSF-1R-independent manner (Fig 5C).
To elaborate on the genotype-specific responses observed, we
examined transcriptional changes in WT and Csf-1r+/− endothelial
cells treated with MCM produced by either WT or Csf-1r+/− micro-
glia. Expression of TJ components claudin-5, occludin and tricellulin
were found to be significantly reduced Csf-1r+/− endothelial cells
following treatment with Csf-1r+/− MCM (Fig 5H–O). Wild-type
endothelial cells also displayed a resistance to Csf-1r+/− MCM, main-
taining tight junction gene expression (Fig 5H–O). With regard to
expression of CSF-1R pathway components, transcription of both
Csf-1 and Il34 was elevated in Csf-1r+/− endothelial cells and in the
case of Il34, Csf-1r+/− MCM induced an upregulatory response in
Csf-1r+/− endothelial cells. In contrast, Csf-1r+/+ MCM inhibited Il34
expression in Csf-1r+/− endothelial cells, suggesting microglia may
regulate endothelial Il34 expression in a CSF-1R dependent manner
(Fig EV4A and C). The response of the macrophage inhibitory factor
(Mif) expression was similar to that of Il34, with an upregulation of
endothelial Mif expression only observed in Csf-1r+/− endothelial
cells treated with Csf-1r+/− MCM (Fig EV4F). Upregulation of Mif
expression has been implicated in the activation of microglial-medi-
ated inflammatory processes and has recently been proposed to be a
biomarker of Alzheimer’s disease (Zhang et al, 2016, 2019). Further-
more, MIF expression has been demonstrated to enhance tight junc-
tion breakdown and blood–brain barrier permeability in stroke (Liu
et al, 2018), and MIF-mediated processes are reported to be signifi-
cantly altered in ALSP frontal cortex white matter (Kempthorne
et al, 2020). The restriction of these transcriptional changes in TJ
components, Il34 and Mif to Csf-1r+/− endothelial cells responding
to soluble factors from Csf-1r+/− microglia indicates CSF-1R as a key
regulator of microglial-endothelial crosstalk.
CSF-1R mutations and inhibition induce blood–brain
barrier disruption
Given the evidence of CAA and the cerebrovascular pathology
apparent in each post-mortem ALSP case we examined, we stained
post-mortem ALSP brain sections for claudin-5, a key mediator of
tight junction function at the BBB. In areas of dense amyloid-beta
◀ Figure 3. Peripheral variant CSF-1R macrophages have altered identity and function.A, B FACS of control and ΔA781_N783 PBMCs using lineage markers for CD3 (T cells), CD14 (monocytes/macrophages), CD19 (B cells), CD16, CD20 and CD56. Cells
negative for all 6 makers were determined to be lineage-negative (Lin−).
C Immunocytochemistry of macrophages differentiated in vitro from control, ΔA781_N783 or P824R PBMCs. Cells were stained for DAPI (blue) and CD68 (red). White
arrows indicate dysmorphic macrophages.
D Immunocytochemistry of macrophages differentiated in vitro from control, ΔA781_N783 or P824R PBMCs. Macrophages were stimulated with LPS and exposed to
fluorescent opsonised latex beads for 1 h before fixation and quantification of bead+ cells via microscopy. Cells were stained using MitoTracker (red) and DAPI
(blue).
E Quantification of phagocytic activity expressed as percentage bead+ cells. P values were calculated using (**P = 0.008, *P = 0.0141, one-way ANOVA with Tukey’s
multiple comparison test, n = 4 assays, error bars indicate SEM).
F Quantification of macrophages displaying an aberrant morphology as indicated in (c), displayed as percentage of dysmorphic cells per image (***P < 0.0005, one-
way ANOVA with Dunnett’s multiple comparison test, data representative of n = 2 independent differentiations, with two fields of view imaged per well, error bars
indicate SEM).
G Western blot for CSF-1R in untreated (Unt) BV2 microglia, or BV2 microglia transfected with non-targeting or Csf-1r targeting siRNA. Corresponding densitometry
(below) representative of technical replicate of n = 3 blots (one-way ANOVA with Dunnett’s multiple comparison, ***P = 0.0003, error bars indicate SEM).
H Immunocytochemistry of untreated and Csf-1r siRNA treated BV2 microglia. BV2 microglia were stimulated with LPS and exposed to fluorescent opsonised latex
beads for 1 h before fixation and quantification of bead+ cells via microscopy. Cells were stained using MitoTracker (red) and DAPI (blue). Arrowheads (white)
indicate bead+ cells.
I Quantification of BV2 phagocytic activity expressed as percentage bead+ cells (data representative of n = 2 independent differentiations, with two fields of view
imaged per well, error bars indicate SEM).
J Immunocytochemistry of microglia isolated from Csf-1rflx/wt;Cx3cr1-Cre− and Csf-1rflx/wt;Cx3cr1-Cre+ P0 mouse pup brains. Microglia were stimulated with LPS and
exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead+ cells via microscopy. Cells were stained using MitoTracker(red).
Arrowheads (white) indicate bead+ cells.
K Quantification of mouse microglial phagocytic activity expressed as percentage bead+ cells (n = 4 assays, error bars indicate SEM).
L Immunocytochemistry of macrophages differentiated in vitro from Csf-1rflx/wt;Cx3cr1-Cre− and Csf-1rflx/wt;Cx3cr1-Cre+ mouse bone marrow. Macrophages were
stimulated with LPS and exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead + cells via microscopy. Cells were stained
using MitoTracker (red) and DAPI (blue). Arrowheads (white) indicate bead+ cells.
M Quantification of mouse macrophage phagocytic activity expressed as percentage bead+ cells. (*P = 0.024, Student’s t-test with Welch’s correction, n = 4 assays,
error bars indicate SEM).
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deposition around blood vessels, we observed a non-linear distribu-
tion of claudin-5 (Fig 6A) in tandem with extravasation of IgG (Fig 6
B) and fibrinogen (Fig 6G) suggestive of BBB disruption. Perivascu-
lar localisation of CD68- and CD163-positive cells (Fig 6E and F)
indicated a recruitment of macrophages to the vasculature. Added
to this, there were also large swathes of GFAP immunoreactivity
(Fig 6C and D) in areas of CAA, suggestive of perivascular astroglio-
sis absent in age-matched controls (Appendix Fig S2). Given the
very clear cerebrovascular pathology observed in these post-mortem
cases, we conducted dynamic contrast-enhanced MRI (DCE-MRI) in
a genetically diagnosed patient with ALSP who had recently become
symptomatic (ΔA781_N783). While the patient had clear periven-
tricular FLAIR enhancements, there was also clear evidence of BBB
disruption in the cortical and deep white matter regions of the brain
(Fig 6H and I). Susceptibility weighted imaging (SWI) showed
evidence of iron deposition in the putamen and in a similar pattern
to BBB disruption (Fig 6J).
Given the dysregulated BBB phenotype in life and in post-
mortem ALSP samples and as CSF-1R can differentially regulate
endothelial–microglial crosstalk, we wanted to elucidate the impact
of disrupted CSF-1R signalling in brain endothelial cells. In this
regard, a dose-dependent decrease in claudin-5 and occludin levels
were observed at 24-h post-stimulation of cells with a known CSF-
1R inhibitor PLX3397 (Fig EV5A and B). This decrease in tight junc-
tion components was accompanied by a concomitant decrease in
transcription of both Cld5 and Ocln at 24 h, which is maintained
through 48 h in the case of Ocln. PLX3397 treatment resulted in an
increase in paracellular flux of FD-4 across a polarised monolayer of
A B
C D
Figure 4. CSF-1R expression in endothelial cells and macrophages affects response to amyloid injection.
A Immunohistochemistry of Csf-1rflx/wt;Cx3cr1-Cre− (top) and Csf-1rflx/wt;Cx3cr1-Cre+ (bottom) mice unilaterally injected with Aβ1-42 in the hippocampus and stained
for IB4 (green), F4/80 (white) and Aβ (red). Scale bars indicate 50 μm.
B Quantification of F4/80 and IB4 immunopositivity following intrahippocampal injection of Aβ1-42. Quantification of immunopositivity in both injected and
uninjected hippocampi of Csf-1rflx/wt;Cx3cr1-Cre− and Csf-1rflx/wt;Cx3cr1-Cre+ mice. (Two-way ANOVA with Sidak’s test for multiple comparisons. Asterisks (*) indicate
comparison to immunopositivity values of the uninjected hippocampus, obliques (#) indicate comparison between Csf-1rflx/wt;Cx3cr1-Cre− and Csf-1rflx/wt;Cx3cr1-Cre+
mice, ## or **P < 0.003, #### or ****P < 0.0001, n = 5 mice per group, error bars indicate SEM.)
C Immunohistochemistry of Csf-1rflx/wt; Tie2-Cre− (top) and Csf-1rflx/wt;Tie2-Cre+ mice (bottom) mice unilaterally injected with Aβ1-42 in the hippocampus and stained
for IB4 (green), F4/80 (white) and Aβ (red).
D Quantification of F4/80 and IB4 immunopositivity following intrahippocampal injection of Aβ1-42. Quantification of immunopositivity in both injected and
uninjected hippocampi of Csf-1rflx/wt;Tie2-Cre− and Csf-1rflx/wt;Tie2-Cre+ mice. (n = 5 mice per group. Two-way ANOVA with Sidak’s test for multiple comparisons.
Asterisks (*) indicate comparison to immunopositivity values of the uninjected hippocampus, *P < 0.01, ***P < 0.0005, error bars indicate SEM).
8 of 17 EMBO Molecular Medicine 13: e12889 | 2021 ª 2020 The Authors




H I J K
L M N O
F G
D
Figure 5. Endothelial–macrophage crosstalk regulates CSF-1R expression and TJs.
A Schematic for experimental design.
B Western blot for CSF-1R in b.End3 cells treated with different BV2 conditioned media or PLX3397, with corresponding densitometry (right). (n = 3 independent BV2
media conditionings and b.End3 treatments, one-way ANOVA with Dunnett’s post-test for multiple comparisons, *P < 0.05, ***P < 0.0005, error bars indicate SEM).
C Western blot for tight junction proteins in b.End3 cells treated with unconditioned, microglia conditioned media or PLX3397.
D Densitometry of tight junction protein changes (top) and transcriptional changes in Tjp1, Ocln and Cld5 (bottom) following conditioned media treatments or 20 μM
PLX3397. (n = 3 independent BV2 media conditionings and b.End3 treatments, one-way ANOVA with Dunnett’s post-test for multiple comparisons, *P < 0.05,
**P < 0.009, error bars indicate SEM).
E Schematic for experimental design.
F Western blot of WT endothelial cells treated with unconditioned or microglia conditioned media (MCM) produced from Csf-1r+/− or PLX3397-inhibited microglia.
G Western blot of Csf-1r+/− endothelial cells treated with unconditioned, Csf-1r+/− MCM or PLX3397 MCM.
H–K qPCR of wild type (blue) or Csf-1r+/− (red) endothelial cells treated with control, Csf-1r+/+ MCM or Csf-1r+/− MCM. Statistical analyses of inter-genotype changes.
(****P < 0.0001, **P < 0.005, Scatter plots represent technical replicates of n = 2 independent primary cell isolations and microglia conditionings, Two-way
ANOVA with multiple comparisons and Sidak’s post-test, error bars indicate SEM).
L–O qPCR of wild type (blue) or Csf-1r+/− (red) endothelial cells treated with control, Csf-1r+/+ MCM or Csf-1r+/− MCM. Statistical analyses of changes relative to
respective untreated Control. (**P < 0.005, *P < 0.05. Scatter plots represent technical replicates of n = 2 independent primary cell isolations and microglia
conditionings, two-way ANOVA with multiple comparisons and Sidak’s post-test, error bars indicate SEM).
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primary brain endothelial cells (Fig EV5E) and accompanying down-
regulation of Cld5 (Fig EV5D). While endothelial expression of CSF-
1R is disputed, these data provide a tentative link between CSF-1R
inhibition and tight junction integrity. Further in vivo characterisa-
tion of the BBB in the endothelial Csf1r−/− mouse will be needed to
directly attribute endothelial CSF-1R loss with a corresponding loss
in TJ integrity within the cerebrovasculature.
Discussion
Within the healthy brain, microglia are the primary cells that
respond to CSF-1 and IL-34. Following ligation to CSF-1R, the ligand
is taken into the cell, reducing the extracellular concentration and
preventing long-term local CSF-1R activity. Within the brain of an
individual with ALSP however, microglia will constitutively express
50% less functional CSF-1R. This likely results in a CNS saturated
with IL-34 and CSF-1 and increased levels of CSF-1 have previously
been observed in the CSF-1R-knockout mouse and indeed in some
mouse models of AD (Dai et al, 2002; Laske et al, 2010). This
increased pool of CSF-1R ligands may also provide a prolonged
opportunity for other cells expressing the receptor to bind ligand
and signal through CSF-1R. Therefore, to date, a major focus has
been to understand and potentially target CSF-1R signalling in
microglial cells in the context of neuropathologies such as AD and
epilepsy.
Here, we sought to understand the role of CSF-1R signalling in
microglial cells in the context of haploinsufficiency of CSF-1R. We
were, however, surprised to find that microglial cells seemed to
adequately tolerate CSF-1R depletion and it was peripheral macro-
phages and endothelial cells that appeared to be impacted more
profoundly. This suggests that, at least in the context of ALSP, the
primary driving force of pathology is at the level of the systemic
immune response to CSF-1R depletion. Intriguingly, the develop-
ment of CAA has been shown to occur in up to 80% of sporadic AD
cases; however, the underlying molecular aetiology of Aβ deposition
around blood vessels is still far from clear. Here, we show that in
genetically diagnosed cases of ALSP, CAA development is clear and
evident in each case. Added to this, we now confirm that there is no
dominant-negative effect of the CSF-1R mutations and they simply
lead to a loss of function in kinase activity.
Our findings suggest that inhibiting CSF-1R signalling as previ-
ously proposed as a potential therapeutic for AD (Dagher et al,
2015; Spangenberg et al, 2019) could in fact exacerbate the human
pathology. CSF-1R inhibition could potentially impact the phago-
cytic capacity of macrophages in addition to reducing peripheral
A B C
D E F
G H I J
Figure 6. Loss of CSF-1R reduces BBB integrity.
A–C (A) IHC of ALSP patient post-mortem tissue for amyloid-β (green) and CLD5 (red), (B) human IgG (green) and PDGFRβ (red), (C) GFAP (green) and CLD5 (red).
ΔA781_N783 and P824R indicate the CSF-1R variant present.
D–H (D) Iba1 (green) and GFAP (red), (E) amyloid-β (green) and CD68 (red), (F) CD163 (green) and CLD5 (red), (G) fibrinogen (green) and CLD5 (red) and (H) FLAIR imaging
of an ALSP patient with the ΔA781_N783 CSF-1R variant. ΔA781_N783 and P824R indicate the CSF-1R variant present.
I T1-weighted DCE-MRI of an ALSP patient with the ΔA781_N783 CSF-1R variant. Colormetric scale indicates the slope of the quantified Gd-BOPTA accumulation, as
an indicator of BBB permeability.
J Susceptibility weighted imaging (SWI) of an ALSP patient with the ΔA781_N783 CSF-1R variant showing iron deposition.
Data information: Note that Fig 6C and F are shown again in Fig EV1 for ease of comparison.
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macrophage-mediated clearance of vascular amyloid-β. Secondly,
attenuated and aberrant microglial CSF-1R signalling will induce
endothelial tight junction re-modelling and BBB permeability as
we have shown in post-mortem ALSP cases in addition to
contrast-enhanced MRI studies in a genetically diagnosed ALSP
patient. Our findings suggest a targeted approach to restoring BBB
integrity while also restoring CSF-1R signalling in macrophages
could drive a therapeutic response in ALSP patients and other AD-
like dementia.
We now propose that symptomatic and genetically diagnosed
individuals with ALSP and potentially other forms of AD-like
neuropathology will respond to CSF-1R and BBB stabilising
approaches to therapy as opposed to CSF-1R inhibition-based
strategies as currently proposed. Interestingly, our data also
strongly suggest that ALSP patients may be amenable and highly
responsive to bone marrow transplantation, with transplantation
potentially slowing the course of neurodegeneration. This has
recently been evidenced in a small series of case reports where
ALSP patients have been shown to stabilise in the months and
years after receiving transplantation for alternative perceived
reasons (Mochel et al, 2019; Gelfand et al, 2020). Understanding
the molecular aetiology of rare neurodegenerative conditions such
as ALSP may be the driving force in identifying novel therapeutic
approaches to more common neuropathies. The suggestion of
microglial cells being a central driving force of pathology should
also be revised to incorporate the critical role played by macro-
phages and endothelial cells.
Materials and Methods
DNA isolation
DNA was isolated from whole blood of live ALSP patients, or from
formalin-fixed paraffin embedded (FFPE) tissue. For whole blood,
2 ml of peripheral blood was added to 2 ml of red blood cell (RBC)
lysis buffer (0.32 M sucrose, 10 mM Tris, 5 mM MgCl2, 0.75% v/v
Triton X-100, pH 7.4). The mixture was inverted and placed on ice
for 3 min and spun at 1,500 g for 15 m at 21°C. The supernatant
was discarded, and pellet resuspended in 2 ml RBC lysis buffer and
6 ml dH2O before being centrifuged again. The washed pellet was
resuspended in proteinase K digest buffer (20 mM Tris, 4 mM
Na2EDTA, 100 mM NaCl, 1% w/v SDS, 0.2 mg/ml proteinase K pH
7.4) and incubated at 55°C overnight. 4 ml of 5.3 M NaCl was added
to the completed digest followed by 0.2 volumes of chloroform.
Tubes were shaken, centrifuged, and the upper aqueous layer
moved to a new tube. DNA was isolated using alcohol precipitation
followed by resuspension in nuclease free water.
FFPE brain tissue was incubated with gentle shaking in xylene
for 15 min at 21°C, centrifuged at 1,500 g for 5 m at 21°C, and
supernatant was removed and replaced with fresh xylene. This
was repeated twice before pelleted tissue was rehydrated by incu-
bating in decreasing concentrations of ethanol, 100, 70, 50%
before incubating in dH2O.As above, the pelleted tissue was incu-
bated overnight in proteinase K digest buffer and DNA was
isolated.
100 ng of DNA was amplified by PCR in a volume of 25 μl using
1 × reaction buffer, 200 μM each of dNTPs, 0.2 μM of forward and
reverse primers, and 1.25 units of DNA Taq polymerase under the
following conditions: 95°C 5 min; (95°C 1 min; 58°C 1 min; 72°C
1 min) × 34; 72°C 5 min; 4°C hold. This produced an amplified
product of 603 bp using the following primers: forward primer 50-
CTCCAGCAGGGACTCCAAAG-30 and reverse primer 50-GGATGCCA
TAGGACCAGAC-30. DNA from the above amplification was purified
using a QIAquick PCR purification kit (Qiagen) and subjected to
direct sequencing using the forward primer (above).
Generation of CSF-1R-expressing constructs
For in vitro work, Native, and ΔA781_N783 CSF-1R cDNA
sequences were synthesised using GeneArt (Thermo Fisher Scien-
tific) and cloned into the AgeI/EcoRI site of the pcDNA3-EGFP
expression plasmid (Addgene). The P824R expression construct was
generated from the native CSF-1R expression plasmid using the Q5®
Site-Directed Mutagenesis Kit (New England Biolabs) and the
following primers: forward 50-TGGATGGCCCGAGAGAGCATCTTTG-
30 and reverse 50-CTTCACAGGCAGGCGGGC-30.
MRI
BBB permeability maps were created using the slope of contrast
agent concentration in each voxel over time, calculated by a linear
fit model as previously described. Thresholds of high permeability
were defined by the 95th percentile of all slopes in a previously
examined control group. All imaging was performed using a 3T
Philips Achieva scanner and included a T1-weighted anatomical
scan (3D gradient echo, TE/TR = 3/6.7 ms, acquisition matrix
268 × 266, voxel size: 0.83 × 0.83 × 0.9 mm), T2-weighted imaging
(TE/TR = 80/3,000 ms, voxel size: 0.45 × 0.45 × 0.4 mm), FLAIR
(TE/TR = 125/11,000 ms, voxel size: 0.45 × 0.45 × 4 mm).
The calculation of pre-contrast longitudinal relaxation time
(T10), the variable flip angle (VFA) method was used (3D T1w-FFE,
TE/TR = 2.78/5.67 ms, acquisition matrix: 240x184, voxel size:
0.68x0.68x5 mm, flip angles: 2, 10, 16 and 24°). Dynamic contrast-
enhanced (DCE) sequence was then acquired (Axial, 3D T1w-FFE,
TE/TR = 2.78/5.6 ms, acquisition matrix: 240x184, voxel size:
0.68x0.68x5 mm, flip angle: 6°, Δt = 6.5 s, temporal repetitions: 70,
total scan length: 7.6 min). An intravenous bolus injection of the
contrast agent gadobenate dimeglumine (Gd-BOPTA, Bracco Diag-
nostics Inc., Milan, Italy) was administered using an automatic
injector after the first three DCE repetitions. All ethical approvals
were in place prior to the initiation of studies on human subjects.
All experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report.
Cell line culture
Human embryonic kidney cells (HEK293, ATCC) were cultured in
Dulbecco’s modified Eagle’s medium containing 4,500 mg/l glucose,
GlutaMAX and 110.0 mg/ml sodium pyruvate (DMEM) supple-
mented with 10% foetal bovine serum (FBS) in a 5% CO2 incubator
at 37°C. One day before transfection, HEK293 cells were seeded on
12-well plates (2.5 × 105 cells per well). The next day, 500 ng of
plasmid containing wild-type or variant CSF-1R cDNA was trans-
fected per well using Lipofectamine 2000 (Invitrogen).
ª 2020 The Authors EMBO Molecular Medicine 13: e12889 | 2021 11 of 17
Conor Delaney et al EMBO Molecular Medicine
For signalling experiments, transfected cells were incubated in
DMEM without serum for 16 h. IL-34 or CSF-1 was added at 10, 50
or 100 ng/ml and cells were incubated for 10 min. Cells were
washed with PBS on ice and proteins were isolated with lysis buffer
(50 mM Tris, 150 mM NaCl, 0.5% w/v sodium deoxycholate, 0.1%
v/v Triton X-100 and 0.1% w/v SDS) with added cOmplete™, Mini
Protease Inhibitor Cocktail (Roche). For treatment with protein turn-
over regulators, cells were treated 24 h after transfection with rapa-
mycin (0.1, 0.5, 1, 5 and 10 μM), 3-MA (0.1, 0.2, 0.5, 1 mM) or
MG132 (0.1, 0.5, 1, 5 μM). Cells were lysed as above at 24 h post-
treatment for rapamycin and 3-MA and at 7 h post-treatment for
MG132. For the MG132 pre-treated signalling experiment, cells
were treated 24 h post-transfection for 1 h in 1 μM MG132 before
being treated with 10, 50 or 100 ng/ml CSF-1 for 10 min and lysed
as above.
The mouse microglial BV2 cell line was kindly provided by the
Lynch lab (TCIN, Trinity College Dublin). Cells were grown in
DMEM with 10% FBS in a 5% CO2 incubator at 37°C, and plated in
1 ml of media at 1.25 × 106 cells per T25 flask for media condition-
ing. Flasks were flooded with 12 ml DMEM, 10% FBS 2 h later. At
24 h postseeding, media was refreshed and BV2 cells grown for
48 h to generate conditioned media. Conditioned media was centri-
fuged at 300 g for 5 min at 21°C, the supernatant passed through a
0.2 μm sterile filter and added to endothelial cultures.
Mouse brain endothelial cells (Bend.3, ATCC) were cultured in
DMEM supplemented with 10% FBS in a 5% CO2 incubator at 37°C.
Bend.3 cells were seeded on 12-well plates (2.5 × 105 cells per well)
and allowed to grow to confluency and treated with BV2-condi-
tioned media for 24 h. Cells were lysed for protein analysis as
above, and in TRK Lysis buffer (Omega Bio-tek) for RNA isolation.
Transfection with Csf-1r Smart Pool (Dharmacon) siRNA was
performed 24 h after cell seeding using Viromer Blue transfection
reagent (Lipocalyx) and 20 pmol siRNA per well.
Immunocytochemistry
HEK293 cells were seeded on 1% fibronectin-coated 1.3 mm tissue
culture coverslips (Sarstedt) in DMEM, 10% FBS. After plasmid
transfection, cells were fixed for 10 min at room temperature with
ice-cold methanol, washed twice with PBS and incubated with 5%
normal goat serum (NGS) before overnight incubation with poly-
clonal rabbit anti-CSF-1R (Invitrogen; PA5-25974, 1:100) at 4°C.
Cells were then washed twice with PBS and incubated with Cy3-
conjugated goat anti-rabbit IgG secondary antibody (1:500; Abcam)
for 2 h at room temperature and counterstained with Hoechst 33258
to visualise nuclei.
Macrophages were seeded in poly-L-lysine coated 8-well cham-
ber slides (Ibidi) at 2.8 × 104 cells/cm2. Macrophages were grown
for 72 h, fixed in 4% PFA for 10 m at RT and stained as above with
rat anti-human CD68 (Abcam) primary antibody and 594-conjugated
goat ant-rat IgG secondary antibody(Invitrogen).
Immunohistochemistry
FFPE sections of autopsied HDLS brains were de-paraffinised in
xylene and rehydrated stepwise through decreasing ethanol
concentrations. Sections were permeabilised by incubating in
methanol for 15 min at −20°C and blocked in 5% NGS, PBS, 0.1%
Triton X-100 for 45 min. Sections were incubated in primary anti-
body in PBS, 1% NGS, 0.1% Triton X-100 overnight at 4°C (CD68
(Santa Cruz, sc-20060, 1:100), anti-beta-amyloid AW7 (kindly
provided by Dominic Walsh, 1:1,000), CLD5 (Invitrogen, 34-1600,
1:200), CD163 (Novocastra, NCL-CD163, 1:200), GFAP (Sigma,
G3893, 1:500), hIgG (Abcam, 97170, 1:300), Fibrinogen (DAKO,
F0111, 1:300), Iba1 (Wako, 019-19741, 1:500)). Slides were washed
three times in PBS and incubated with 594- and 488-conjugated
goat anti-rabbit and anti-mouse secondary antibodies (1:500; Invit-
rogen) for 3 h at 21°C and counterstained with Hoechst 33258 to
visualise nuclei.
For IHC of amyloid-injected brains, mice were killed and the
brains quickly removed and embedded in optimal cutting tempera-
ture compound (VWR), snap-frozen in liquid nitrogen and stored at
−20°C prior to slicing on a cryostat. Mouse brain cryosections
(20 μm thick) were post-fixed in ice-cold methanol for 10 min at
room temperature and washed three times in PBS. Sections were
then incubated with 5% NGS before overnight incubation with
primary antibodies at 4°C (F4/80 (Abcam; ab6640, 1:100), anti-beta-
amyloid AW7 (kindly provided by Dominic Walsh, 1:1,000).
Sections were double-stained with isolectin-IB4-Alexa Fluor 488
1:300 (Life Technologies), to label vessels and macrophages.
Following three washes in PBS, sections were incubated with Cy3-
conjugated goat anti-rabbit IgG and 405-conjugated goat anti-rat
secondary antibody (1:500; Abcam) for 2 h at room temperature,
washed three times with PBS and counterstained with Hoechst
33258. Sections were mounted and with Aqua Polymount (Poly-
sciences). Sections were imaged with a Zeiss LSM 710 confocal laser
scanning microscope. For quantification, pixel intensity was thresh-
olded uniformly across all images and the ratios of pixel intensity
values between the injected and uninjected hippocampus were
compared. All image analysis was performed using ImageJ
(National Institutes of Health, Rockville, MD, USA).
SDS–PAGE and Western Blotting
Whole cell lysates were diluted in dH2O and 5X Pierce™ Lane
Marker Reducing Sample Buffer (Thermo Fisher) and 10 μg total
protein loaded per well for separation by SDS–PAGE. Gels were
transferred onto methanol-activated polyvinylidene difluoride
(PVDF) membranes (Immobilon-P Transfer Membrane, Merck Milli-
pore) via semi-dry transfer. Transferred membranes were re-acti-
vated with methanol and blocked under slight agitation in TBS-
Tween-20 containing 3% w/v Marvel non-fat dry milk for 1 h at
room temperature. Blocked membranes were washed three times
with TBS-Tween-20 and treated with primary antibody overnight at
4°C (CLD5 (Invitrogen, 34-1600, 1:1,000), ZO1 (Invitrogen, 402200,
1:1,000), OCLN (Novus Biotech, NBP1-87402, 1:1,000), Triellulin
(Invitrogen, 488400, 1:1,000), GAPDH (Cell Signalling, 2118,
1:4,000), phospho-ERK (Cell Signalling, 9101, 1:2,000), total ERK
(Cell Signalling, 9102, 1:1,000), CSF-1R (Abcam, ab221684,
1:1,000), β-ACTIN (Abcam, ab8227, 1:4,000) ). Membranes were
washed three times for 5 min in TBS-Tween-20 and incubated with
horse radish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibody (Sigma) diluted 1:2,000 in TBS-Tween-20 for
2 h at room temperature. Secondary antibody was removed and
membranes were washed four times for 5 min in TBS-Tween-20.
Blots were developed by enhanced chemiluminescence (ECL). A 1:1
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mix of WesternBright ECL Luminol/enhancer solution and Peroxide
Chemiluminescent solution (Advansta) was incubated at room
temperature for 2 min before being directly added onto washed
blots. The LiCor C-Digit Blot Scanner was used to detect chemilumi-
nescence over a 12 min exposure time.
FACS
PBMCs isolated from HDLS donor blood were seeded in round
bottomed 96-well plates in Roswell Park Memorial Institute (RPMI)
media with 10% FBS at 4 × 105 cells per well and incubated in a 5%
CO2 incubator at 37°C overnight. Cells were centrifuged at 300 g for
5 min and blocked for 10 min with 50 μl 10% human AB serum, 1%
FBS in PBS. Blocked PBMCs were incubated in Live/Dead Aqua
(1:500; Life technologies (Fisher/Invitrogen) L34957 ) for 30 min,
washed in PBS and incubated in fluorochrome-labelled primary anti-
body diluted 1:10 in PBS, 1% FBS for 20 min at 4°C. (Lin FITC
(BioLegend 348801), CD3 PerCP (Miltenyi 130-100-458), CD19
APCCy7 (Miltenyi 130-098-073), CD14 PacBlue (Miltenyi 130-098-
058). Cells were washed twice with PBS 1% FBS and analysed by
flow cytometry immediately. Gating during analysis was based on
fluorescence minus one controls. Flow cytometry was carried out on
a BD LSRFortessa cell analyser and analysed using FlowJo software
(Tree Star).
Primary mouse cerebral microvessel isolation and culture
Microvessels were isolated from cortical grey matter of experimen-
tal mice by collagenase/dispase (Roche) digestion and bovine
serum albumin density gradient centrifugation. Purified vessels
were seeded onto collagen IV/fibronectin-coated tissue culture
plates or Corning (Corning) HTS 24-well Transwell polyester
inserts (0.4 μm pore size, vessels from five mouse brains per 3 ml)
at high density. Cells were grown in EGM2-MV (Lonza) (with
5 μg/ml puromycin during the first 3 days for endothelial cell
selection) for 2–3 weeks until their transendothelial electrical resis-
tance values plateaued.
Transwell permeability assays
Mouse brain endothelial cells (5 × 104 cells per well) were grown to
confluence on 1% fibronectin-coated Corning HTS 24-well Tran-
swell polyester inserts with a pore size of 0.4 μm and treated with
PLX3397 for 24 h. 200 μl of 1 mg/ml of FITC–4kDa Dextran (Sigma-
Aldrich) in EGM2-MV2 was added to the apical chamber of each
well, and the cells were incubated at 37°C. Sampling aliquots were
taken from the basolateral chamber and replaced with fresh medium
every 15 min for 2 h and then transferred to 96-well plates (Nunc).
FITC-Dextran fluorescence was determined using a spectrofluorome-
ter (Optima Scientific) at an excitation wavelength of 485 nm and
an emission wavelength of 520 nm. Relative fluorescence units were
converted to values of nanograms per millilitre, using FITC-Dextran
standard curves, and were corrected for background fluorescence
and serial dilutions over the course of the experiment. The apparent
permeability coefficient (Papp) for each treatment was calculated
using the following equation:
Pappðcm=sÞ¼ ðdQ=dTÞðA  C0Þ
where dQ/dT (μg/s) is the rate of appearance of FITC-Dextran on
the receiver side after application, A (cm2) is the effective surface
area of the insert size, and C0 (μg/ml) is the initial FITC-Dextran
concentration on the donor side. dQ/dT is the slope m (y = mx + c)
calculated by plotting the cumulative amount (Q) versus time (s).
Primary mouse microglia isolation and culture
Microglia were isolated as described in Cox et. al (Cox et al, 2015).
Whole brains were dissected from Cx3Cr1-Cre+/−;Csf-1rwt/Flx or
Cx3Cr1-Cre−/−;Csf-1rwt/Flx littermates, chopped and added to work-
ing media (DMEM GlutaMAX containing 10% FBS, and penicillin/
streptomycin (10 µg/ml). Brains were homogenised using a 5 ml
pipette, passed through a 40 μm sterile mesh filter, and spun at
300 g for 5 min at 21°C. Pelleted cells were resuspended in working
media, plated in 1 ml per T25 flask and incubated in a humidified
environment at 37°C, 5% CO2. 5 ml of working media was added
3 h later following cell attachment. After 24 h, media was supple-
mented with 20 ng/ml colony stimulating factor 1 (CSF-1) and
10 ng/ml colony stimulating factor 2 (CSF2) (R&D Systems). Mixed
glial cultures were grown for 14 days, changing media every 4 days.
On day 14, flasks were wrapped with parafilm and shaken at
110 rpm at 21°C for 1 h to isolate nonadherent microglial cells.
Suspended cells were centrifuged at 300 g for 5 min at 21°C seeded
at 5 × 104 cells/cm2 in minimal volumes of working media and
grown in a 5% CO2 incubator at 37°C. After 2 h, working media
containing any unattached cells was removed and replaced.
For media conditioning, 7.3 × 105 cells were seeded into 6-well
tissue culture plates. Microglia were grown for 24 h and had media
replaced and collected 24 h later. Conditioned media was centri-
fuged, sterile filtered and diluted at a 2:1 ratio in EGM2-MV2 before
adding to endothelial cultures.
BMDM isolation
Femurs and tibiae were removed from Cx3Cr1-Cre+/−;Csf-1rwt/Flx or
Cx3Cr1-Cre−/−;Csf-1rwt/Flx adult mice and the fat and muscles cut
away to leave clean bones.. A 20-ml syringe was filled with
DMEM + Glutamax medium supplemented with 10% FCS and 1%
P/S, a 27 G needle attached, and the bone marrow was flushed
through the bones into a sterile Petri dish. Aggregates were broken
up by passing the cells repeatedly through a 20-ml syringe with a 19
G needle attached. The cells were transferred to a 50-ml tube and
centrifuged at 300 g for 5 min. Cells were resuspended in the
medium with 25 ng/ml colony stimulating factor CSF-1 and plated
into 6 dishes/mouse, with 10 ml of media per mouse. Plates were
incubated at 37°C with 5% CO2. Cells were fed on day 3 by adding
10 ml of medium with 25 ng/ml of M-CSF per dish. On day 6,
trypsin-EDTA was used to remove the cells from the dishes. Cells
were seeded onto 13mm tissue culture coverslips and allowed to
grow for 24 h before use.
PBMC isolation and macrophage differentiation
Whole blood was collected in EDTA-coated tubes and diluted 1:1
with PBS, 2% FBS. 20 ml of the blood/PBS mixture was layered
onto 10 ml of Lymphoprep (Stemcell Technologies) and centrifuged
at 400 g for 45 min with brake and acceleration set to zero. The
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plasma layer was removed and PBMCs collected using a Pasteur
pipette and washed twice in PBS, 2% FBS followed by a final wash
in RPMI. Cells were resuspended in RPMI, 50% FBS, 10% DMSO
and frozen.
To generate macrophages, PBMCs were thawed and transferred to
complete RPMI, 20% heat-inactivated FBS, 50 ng/ml CSF-1 (cRPMI)
and grown for 48 h, rinsed 3 times with RPMI to remove loosely
adhered cells and allowed to grow in cRPMI until cells expanded to
confluency, changing media every 2 days. Differentiated macro-
phages were trypsinised and seeded at 2.8 × 104 cells/cm2.
Phagocytosis assay
Microglia, BMDM and PBMC-derived macrophages were treated
with 10 ng/ml lipopolysaccharide (LPS) for 24 h prior to being
assayed. Latex beads, polystyrene amine modified (yellow-green)
(Sigma) were pre-opsonised in FBS (1:5) at 37°C for 1 h. Opsonised
beads were diluted 1:10,000 in media and added to cells for 1 h.
Cells were washed with ice-cold PBS 3 times to remove surface
bound beads and fixed in 4% PFA for 10 min and stained with Mito-
Tracker Orange CMTMRos for 30 min. Fixed cells were imaged on a
Zeiss LSM 710 confocal microscope. Images were analysed by
counting bead+ cells in multiple fields of view over 4 replicates and
the data expressed as % bead+ cells per genotype.
Intrahippocampal AB1-42 injection
Mice (8–12 weeks old) were anaesthetised using a ketamine/meta-
domidine mixture administered via intraperitoneal injection and
placed in a stereotaxic frame. An incision was made to expose the
skull, and burr holes were made using a surgical drill either above
the dorsal hippocampus or the medial prefrontal cortex (mPFC).
AggreSureTM Beta-Amyloid 1–42 (AnaSpec) was reconstituted in
50 mM Tris, 150 mM NaCl, pH 7.2 at 0.25 mg/ml per manufacturer’s
instructions. A Hamilton syringe was loaded with 10 μl reconstituted
amyloid, and the needle was slowly lowered into the dorsal
hippocampus: (co-ordinates: A/P = −1.9 mm; M/L = 1.55 mm;
D/V = 1.75 mm). 5.0 μl of Beta-Amyloid 1-42 was then injected at a
rate of 0.5 μl per min, and once complete, the needle was left in
place for 5 min. Anaesthesia was reversed with an intraperitoneal
injection of atipamezole and placed in an incubator until recovered.
Mice were sacrificed 3 days post-injection and brains taken for IHC.
Quantitative real-time PCR
RNA was isolated using the E.Z.N.A. Total RNA Kit I (Omega Bio-
tek) and cDNA synthesis was performed using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). cDNA was diluted
1:10 with nuclease free water and quantitative RT–PCR was
performed on a StepOnePlus (Applied Biosystems) machine using
SensiFAST™ SYBR® Hi-ROX Kit (Bioline) and primers listed in
Table 1. Cycle threshold (Ct) values were to β-actin and to untreated
controls using the delta cT method.
Stress and toxicity microarray
HEK293 cells were transfected with native or P824R CSF-1R-
expressing plasmids and lysed at 24 h post-transfection in TRK
lysis buffer. RNA was isolated and cDNA synthesised using the
RT2 First Strand Synthesis Kit (Qiagen), with DNase I digests and
genomic DNA elimination steps included. Native and P824R-
transfected cell cDNA were analysed using the RT2 Profiler™ PCR
Array Human Stress & Toxicity PathwayFinder (Qiagen) per
manufacturer’s instructions.
Statistical analyses
GraphPad Prism 8.0 (GraphPad Software) was used for statistical
analyses. Statistical analysis was performed using Student’s t-test,
with significance represented by a P value of ≤ 0.05. For multi-
ple comparisons, ANOVA was used with a Dunnett post-test and
significance represented by a P value of ≤ 0.05. The omnibus K2
(D’Agostino-Pearson) test was used in GraphPad Prism 8 to test
for Gaussian distribution of data. G*Power was used a priori to
calculate an appropriate sample size to ensure adequate power
for experiments. All animal experiments were conducted in a
blinded fashion, with the analysis similarly performed by an
experimenter blinded to the conditions. Randomisation was
used for any experiments using injected material such as
amyloid-β. Littermate controls were used for knockout studies
and retroactively genotyped.
Animals
All studies carried out in the Smurfit Institute of Genetics in Trinity
College Dublin (TCD) adhere to the principles laid out by the inter-
nal ethics committee at TCD and all relevant national licences were
obtained prior to commencement of all studies. All mice were bred
on-site in the specific pathogen-free unit at the Smurfit Institute of
Genetics in TCD.
Data and software availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
Table 1. RT–PCR primer sequences.
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Impact
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rity could also show promise for multiple other neurodegenerative
conditions, which currently have no approved therapies.
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